$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

$xers Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000186709624000162 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$54.27M	$48.07M
YoY Change	12.31%	26.46%
Cost Of Revenue	$13.59M	$7.790M
YoY Change	65.77%	3.04%
Gross Profit	$40.68M	$40.28M
YoY Change	1.38%	32.27%
Gross Profit Margin	74.95%	83.79%
Selling, General & Admin	$44.97M	$39.99M
YoY Change	20.6%	6.27%
% of Gross Profit	110.56%	99.3%
Research & Development	$5.888M	$5.759M
YoY Change	16.96%	-5.39%
% of Gross Profit	14.48%	14.3%
Depreciation & Amortization	$3.018M	$2.991M
YoY Change	-2.65%	-3.52%
% of Gross Profit	7.42%	7.43%
Operating Expenses	$50.86M	$45.75M
YoY Change	20.17%	4.64%
Operating Profit	-$12.89M	-$8.187M
YoY Change	162.43%	-48.76%
Interest Expense	-$6.589M	-$6.673M
YoY Change	-196.9%	-202.66%
% of Operating Profit
Other Income/Expense, Net	-$6.169M	-$6.069M
YoY Change	-18.98%	33.74%
Pretax Income	-$19.06M	-$14.26M
YoY Change	52.13%	-30.53%
Income Tax	-$3.324M	$749.0K
% Of Pretax Income
Net Earnings	-$15.74M	-$15.01M
YoY Change	29.12%	-24.38%
Net Earnings / Revenue	-29.0%	-31.22%
Basic Earnings Per Share	-$0.11	-$0.10
Diluted Earnings Per Share	-$0.11	-$0.10
COMMON SHARES
Basic Shares Outstanding	149.0M shares	148.3M shares
Diluted Shares Outstanding	149.0M shares	148.3M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.40M	$77.57M
YoY Change	5.15%	-3.88%
Cash & Equivalents	$59.23M	$57.60M
Short-Term Investments	$10.17M	$19.96M
Other Short-Term Assets	$7.140M	$7.355M
YoY Change	-10.75%	-11.39%
Inventory	$45.12M	$42.98M
Prepaid Expenses	$7.140M	$7.355M
Receivables	$41.14M	$42.44M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$162.8M	$170.3M
YoY Change	3.0%	9.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.613M	$5.833M
YoY Change	-9.25%	-10.97%
Goodwill	$22.86M	$22.86M
YoY Change	0.0%	0.0%
Intangibles	$101.6M	$104.3M
YoY Change	-9.64%	-9.41%
Long-Term Investments
YoY Change
Other Assets	$5.443M	$5.494M
YoY Change	13.23%	14.27%
Total Long-Term Assets	$158.3M	$161.4M
YoY Change	-6.73%	-6.73%
TOTAL ASSETS
Total Short-Term Assets	$162.8M	$170.3M
Total Long-Term Assets	$158.3M	$161.4M
Total Assets	$321.1M	$331.7M
YoY Change	-2.04%	0.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.451M	$5.798M
YoY Change	-38.31%	-50.11%
Accrued Expenses	$23.54M	$23.49M
YoY Change	23.44%	21.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.06M
YoY Change
Total Short-Term Liabilities	$91.01M	$75.49M
YoY Change	4.57%	-5.26%
LONG-TERM LIABILITIES
Long-Term Debt	$216.2M	$230.5M
YoY Change	13.56%	22.47%
Other Long-Term Liabilities	$8.548M	$7.710M
YoY Change	131.03%	190.72%
Total Long-Term Liabilities	$8.548M	$7.710M
YoY Change	131.03%	190.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$91.01M	$75.49M
Total Long-Term Liabilities	$8.548M	$7.710M
Total Liabilities	$349.4M	$351.0M
YoY Change	7.87%	11.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$666.7M	-$651.0M
YoY Change	10.45%	10.08%
Common Stock	$15.00K	$15.00K
YoY Change	7.14%	7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$28.32M	-$19.29M
YoY Change
Total Liabilities & Shareholders Equity	$321.1M	$331.7M
YoY Change	-2.04%	0.9%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$15.74M	-$15.01M
YoY Change	29.12%	-24.38%
Depreciation, Depletion And Amortization	$3.018M	$2.991M
YoY Change	-2.65%	-3.52%
Cash From Operating Activities	-$8.305M	-$10.35M
YoY Change	-43.16%	-24.69%
INVESTING ACTIVITIES
Capital Expenditures	$87.00K	$397.0K
YoY Change	-74.41%	-74.39%
Acquisitions
YoY Change
Other Investing Activities	$10.00M	$5.000M
YoY Change	-33.33%	-50.0%
Cash From Investing Activities	$9.914M	$4.603M
YoY Change	-32.37%	-45.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-83.00K	659.0K
YoY Change	18.57%	19.82%
NET CHANGE
Cash From Operating Activities	-8.305M	-10.35M
Cash From Investing Activities	9.914M	4.603M
Cash From Financing Activities	-83.00K	659.0K
Net Change In Cash	1.526M	-5.086M
YoY Change	-7730.0%	7.3%
FREE CASH FLOW
Cash From Operating Activities	-$8.305M	-$10.35M
Capital Expenditures	$87.00K	$397.0K
Free Cash Flow	-$8.392M	-$10.74M
YoY Change	-43.87%	-29.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3495000	usd
CY2023Q4	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	22149000	usd
CY2023Q4	xers	Accruedreturnsreserve Accruedreturnsreserve	14198000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	19109000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1167000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95193000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	190932000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34764000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1379000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2268000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4848000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	329384000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	138130715	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	138130715	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-617025000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6782000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	322602000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38008000	usd
CY2023Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	7555000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6087000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37635000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2710000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15979000	usd
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	1223000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-601000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6069000	usd
CY2024Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-14256000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	749000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-15005000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	5000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2928000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-49000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13641000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6782000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18980000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q2	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	300000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27657000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	104343000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23510000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	610254000	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	53987000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-781000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3968000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2140000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4538000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10497000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8095000	usd
CY2023Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-20517000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-32929000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-37351000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-675000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1056000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-675000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33985000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36676000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-49000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-5000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-55000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19891000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148345549	shares
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5307000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23494000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23510000	usd
CY2024Q2	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	23275000	usd
CY2024Q2	xers	Accruedreturnsreserve Accruedreturnsreserve	16197000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	420000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	997000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	75488000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	230481000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34016000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3324000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7710000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	351019000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148936727	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148936727	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	631740000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-651010000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	331733000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-19286000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48065000	usd
CY2024Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	7790000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5759000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39993000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2710000	usd
CY2024Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	56252000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8187000	usd
CY2024Q2	us-gaap	Interest Income Other InterestIncomeOther	1291000	usd
CY2024Q2	xers	Debt Refinancing Costs DebtRefinancingCosts	0	usd
	xers	Debt Refinancing Costs DebtRefinancingCosts	0	usd
	xers	Debt Refinancing Costs DebtRefinancingCosts	2690000	usd
	xers	Debt Refinancing Costs DebtRefinancingCosts	0	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7964000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	6528000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	14996000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	12744000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-19842000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14999000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148345549	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	137250465	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	137250465	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	45187000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16834000	usd
CY2023Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	743677	shares
CY2023Q1	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	863000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2564000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	30048000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-19842000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	32000	usd
CY2023Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	13525000	shares
CY2023Q2	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	25000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	549000	usd
CY2024Q1	xers	Stock Issued During Period Value Settlement Of Contingent Value Rights StockIssuedDuringPeriodValueSettlementOfContingentValueRights	15803000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	459000	usd
CY2024Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	1437592	shares
CY2024Q1	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	3434000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3767000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-9178000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-15005000	usd
CY2024Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	23230	shares
CY2024Q2	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	51000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4233000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	710000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-19286000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36676000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	607000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	750000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5421000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5421000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	482000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	812000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1380000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1107000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	340000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	373000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1056000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-675000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5492000	usd
	xers	Adjustment For Change In Fair Value Of Contingent Value Rights AdjustmentForChangeInFairValueOfContingentValueRights	-3968000	usd
	xers	Adjustment For Change In Fair Value Of Contingent Value Rights AdjustmentForChangeInFairValueOfContingentValueRights	-2140000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3243000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-605000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1577000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-827000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4597000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11250000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6063000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7015000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	442000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11206000	usd
	xers	Increase Decrease In Accrued Trade Discounts And Rebates IncreaseDecreaseInAccruedTradeDiscountsAndRebates	1126000	usd
	xers	Increase Decrease In Accrued Trade Discounts And Rebates IncreaseDecreaseInAccruedTradeDiscountsAndRebates	216000	usd
	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	1999000	usd
	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	147000	usd
	xers	Increase Decrease In Supply Agreement Liabilities IncreaseDecreaseInSupplyAgreementLiabilities	0	usd
	xers	Increase Decrease In Supply Agreement Liabilities IncreaseDecreaseInSupplyAgreementLiabilities	-6720000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1064000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	5961000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1829000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1681000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30651000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39884000	usd
	xers	Proceeds Payments From Capital Expenditures ProceedsPaymentsFromCapitalExpenditures	-561000	usd
	xers	Proceeds Payments From Capital Expenditures ProceedsPaymentsFromCapitalExpenditures	-1786000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	29486000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	43741000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	15000000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	10000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15047000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35527000	usd
	xers	Proceeds From Refinancing Of Debt ProceedsFromRefinancingOfDebt	50000000	usd
	xers	Proceeds From Refinancing Of Debt ProceedsFromRefinancingOfDebt	0	usd
	xers	Debt Refinancing Payment Of Debt Discount DebtRefinancingPaymentOfDebtDiscount	11831000	usd
	xers	Debt Refinancing Payment Of Debt Discount DebtRefinancingPaymentOfDebtDiscount	0	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	710000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	549000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	459000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	32000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3485000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	888000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35853000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-307000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9845000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-75718000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71674000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126314000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61829000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50596000	usd
	us-gaap	Interest Paid Net InterestPaidNet	8320000	usd
	us-gaap	Interest Paid Net InterestPaidNet	15206000	usd
	xers	Noncash Shares Issued For Settlement Of Contingent Value Rights Liability NoncashSharesIssuedForSettlementOfContingentValueRightsLiability	15803000	usd
	xers	Noncash Shares Issued For Settlement Of Contingent Value Rights Liability NoncashSharesIssuedForSettlementOfContingentValueRightsLiability	0	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57604000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46170000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4225000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4426000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61829000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50596000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization and nature of the business <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of business </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Xeris Biopharma Holdings, Inc. ("Xeris Biopharma" or the "Company") is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing clinically meaningful products across a range of therapies. The Company currently has three commercially available products: Gvoke, a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia; Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome approved by the Food and Drug Administration ("FDA") in December 2021; and Keveyis, the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis ("PPP"). The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As used herein, the "Company" or "Xeris" refers to Xeris Pharmaceuticals, Inc. ("Xeris Pharma") when referring to periods prior to the acquisition of Strongbridge Biopharma plc ("Strongbridge") on October 5, 2021 and to Xeris Biopharma when referring to periods on or subsequent to October 5, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, Gvoke Kit and Ogluo (glucagon).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to a number of risks similar to other specialty pharmaceutical companies, including, but not limited to, successful commercialization and market acceptance of available products and any future products, if and when approved, successful development of product candidates, the development of new technological innovations by competitors, and protection of intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred operating losses since inception and has an accumulated deficit of $651.0 million as of June 30, 2024. The Company expects to continue to incur net losses for at least the next 12 months beyond the issuance date of these condensed consolidated financial statements. Based on the Company's current operating plans and existing working capital at June 30, 2024, the Company believes that its cash resources are sufficient to sustain operations and capital expenditure requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If needed, the Company may elect to finance its operations through equity or debt financing along with revenues. There can be no assurance that such funding may be available to the Company on acceptable terms, or at all, or that the Company will be able to successfully market and sell Gvoke, Recorlev and Keveyis. Market volatility resulting from geopolitical instability resulting from the ongoing military conflicts between Russia and Ukraine and Israel and Hamas, rising interest rates, inflationary pressures, the tightening of lending standards, any further deterioration in the macroeconomic economy or financial services industry resulting from actual or potential bank failures, or other factors could also adversely impact the Company's ability to access capital as and when needed. The issuance of equity securities may result in dilution to stockholders. If the Company raises additional funds through the issuance of additional debt, which may have rights, preferences and privileges senior to those of the Company's common stockholders, the terms of the debt could impose significant restrictions on the Company's operations. The failure to raise funds as and when needed could have a negative impact on the Company's financial condition and ability to pursue its business strategies. If additional funding is not secured when required, the Company may need to delay or curtail its operations until such funding is received, which would have a material adverse impact on the business prospects and results of operations.</span></div>
CY2024Q2	xers	Number Of Commercially Available Products NumberOfCommerciallyAvailableProducts	3	commerciallyavailableproduct
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-651000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses included in the financial statements and accompanying notes. Actual results could differ from those estimates.
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48065000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38008000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	88703000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71204000	usd
	xers	Debt Securities Available For Sale Average Remaining Maturity DebtSecuritiesAvailableForSaleAverageRemainingMaturity	P0Y2M12D
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19971000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	19964000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5004000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5002000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	23910000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17404000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11302000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10959000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7765000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10475000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	42977000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	38838000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3900000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2400000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12476000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12007000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6643000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6036000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5833000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5971000	usd
CY2023Q2	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	400000	usd
	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	600000	usd
	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	800000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	132000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	132000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	22236000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	109764000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	5422000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10843000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10293000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8643000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8643000	usd
CY2024Q2	xers	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	60499000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	104343000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12825000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16956000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	6670000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1374000	usd
CY2024Q2	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	441000	usd
CY2023Q4	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	523000	usd
CY2024Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	803000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	598000	usd
CY2024Q2	xers	Accruedresearchcosts Accruedresearchcosts	621000	usd
CY2023Q4	xers	Accruedresearchcosts Accruedresearchcosts	960000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2134000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3099000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23494000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	230481000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	190932000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	15200000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	33574000	usd
CY2024Q2	xers	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	200000000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	248774000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	8000000.0	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	15000000.0	usd
CY2024Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	800000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1400000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	6500000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	12700000	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	600000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1100000	usd
	us-gaap	Professional Fees ProfessionalFees	2700000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	94012	shares
CY2024Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	57604000	usd
CY2024Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	19964000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	4225000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	420000	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1000	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	67449000	usd
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	5002000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	4225000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	19109000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1379000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	8000	usd
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4714982	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1822000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9199744	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.22
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M2D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	229417	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	190	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	26962	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.44
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8943175	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y3M21D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8943175	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y3M21D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8840519	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y3M7D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.45
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	2.02
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.10
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4233000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2928000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5492000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P11Y2M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.119
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	839000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	440000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1204000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	918000	usd
CY2024Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20043000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20043000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1340000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1350000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2680000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1763000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	325000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	302000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	566000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	652000	usd
CY2024Q2	us-gaap	Sublease Income SubleaseIncome	52000	usd
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	54000	usd
	us-gaap	Sublease Income SubleaseIncome	105000	usd
	us-gaap	Sublease Income SubleaseIncome	108000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1613000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1598000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	3141000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2307000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2290000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6080000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6232000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6389000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6549000	usd
CY2024Q2	xers	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	45441000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	72981000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	33658000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	39323000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5307000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34016000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	39323000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50010550	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43689554	shares
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
xers-20240630_cal.xml	Edgar Link	unprocessable
0001867096-24-000162-index-headers.html	Edgar Link	pending
0001867096-24-000162-index.html	Edgar Link	pending
0001867096-24-000162.txt	Edgar Link	pending
0001867096-24-000162-xbrl.zip	Edgar Link	pending
a2024q210-qexhibit311.htm	Edgar Link	pending
a2024q210-qexhibit312.htm	Edgar Link	pending
a2024q210-qexhibit321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
strongbridge_regissupply.htm	Edgar Link	pending
strongbridge_regissupply001.jpg	Edgar Link	pending
strongbridge_regissupply002.jpg	Edgar Link	pending
strongbridge_regissupply003.jpg	Edgar Link	pending
strongbridge_regissupply004.jpg	Edgar Link	pending
strongbridge_regissupply005.jpg	Edgar Link	pending
strongbridge_regissupply006.jpg	Edgar Link	pending
strongbridge_regissupply007.jpg	Edgar Link	pending
strongbridge_regissupply008.jpg	Edgar Link	pending
strongbridge_regissupply009.jpg	Edgar Link	pending
strongbridge_regissupply010.jpg	Edgar Link	pending
strongbridge_regissupply011.jpg	Edgar Link	pending
strongbridge_regissupply012.jpg	Edgar Link	pending
strongbridge_regissupply013.jpg	Edgar Link	pending
strongbridge_regissupply014.jpg	Edgar Link	pending
strongbridge_regissupply015.jpg	Edgar Link	pending
strongbridge_regissupply016.jpg	Edgar Link	pending
strongbridge_regissupply017.jpg	Edgar Link	pending
strongbridge_regissupply018.jpg	Edgar Link	pending
strongbridge_regissupply019.jpg	Edgar Link	pending
xeris-lonzacsa.htm	Edgar Link	pending
xeris-lonzacsa001.jpg	Edgar Link	pending
xeris-lonzacsa002.jpg	Edgar Link	pending
xeris-lonzacsa003.jpg	Edgar Link	pending
xeris-lonzacsa004.jpg	Edgar Link	pending
xeris-lonzacsa005.jpg	Edgar Link	pending
xeris-lonzacsa006.jpg	Edgar Link	pending
xeris-lonzacsa007.jpg	Edgar Link	pending
xeris-lonzacsa008.jpg	Edgar Link	pending
xeris-lonzacsa009.jpg	Edgar Link	pending
xeris-lonzacsa010.jpg	Edgar Link	pending
xeris-lonzacsa011.jpg	Edgar Link	pending
xeris-lonzacsa012.jpg	Edgar Link	pending
xeris-lonzacsa013.jpg	Edgar Link	pending
xeris-lonzacsa014.jpg	Edgar Link	pending
xeris-lonzacsa015.jpg	Edgar Link	pending
xeris-lonzacsa016.jpg	Edgar Link	pending
xeris-lonzacsa017.jpg	Edgar Link	pending
xeris-lonzacsaamendment1.htm	Edgar Link	pending
xeris-lonzacsaamendment1001.jpg	Edgar Link	pending
xeris-lonzacsaamendment1002.jpg	Edgar Link	pending
xers-20240630.htm	Edgar Link	pending
xers-20240630.xsd	Edgar Link	pending
xers-20240630_def.xml	Edgar Link	unprocessable
xers-20240630_lab.xml	Edgar Link	unprocessable
xers-20240630_pre.xml	Edgar Link	unprocessable
xers-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

2024 Q3 Form 10-Q Financial Statement

#000186709624000162 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS Xeris Biopharma Holdings, Inc. Stock $xers

2024 Q3 Form 10-Q Financial Statement

#000186709624000162 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers